Fulcrum Therapeutics to merge with Slate Medicines in reverse merger deal
The combined company will focus on Slate's migraine pipeline and raise $245 million in a private placement to fund operations into 2029.
SEC filing
Latest
2 stories
Monday, August 17
Monday, August 10
Fulcrum Therapeutics names new principal accounting officer as Tourangeau exits
The company's CFO Alan Musso takes on the added role effective August 7, 2026, following the planned departure of Greg Tourangeau.
SEC filing